Filing Flows › Autolus Therapeutics (AUTL) › Q4 2024
Autolus Therapeutics (AUTL) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 20, 2025
Autolus Therapeutics (AUTL) reported revenue of $29K for the fourth quarter 2024 (Q4 2024).
Autolus Therapeutics, Q4 2024: revenue $29K, net loss $27.6M, operating cash flow −$37.9M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $29K | — | — |
| Operating profit | −$75.9M | — | — |
| Net earnings | −$27.6M | — | — |
| Operating cash flow | −$37.9M | — | — |
What changed
Revenue was $29K in Q4 2024.
Operating costs exceeded revenue by $75.9M, an operating margin of -261600.0%. The quarter ended with a net loss of $27.6M. Non-operating items added $49.7M, -190% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$37.9M. Non-cash charges added back $1.9M of depreciation and amortization and $6.2M of share-based compensation. Working capital and other items used $18.5M. Capital expenditures of $11.1M exceeded it, leaving free cash flow of −$49.0M.
Questions
What was Autolus Therapeutics' revenue in the fourth quarter 2024?
Autolus Therapeutics (AUTL) reported revenue of $29K for the fourth quarter 2024 (Q4 2024).